| Dr Bruce Steven Chozick, MD | |
|
1000 Asylum Ave, Suite 2107a, Hartford, CT 06105-1770 | |
| (860) 714-9840 | |
| Not Available |
| Full Name | Dr Bruce Steven Chozick |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 36 Years |
| Location | 1000 Asylum Ave, Hartford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386686897 | NPI | - | NPPES |
| 001372002 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 37200 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| John Dempsey Hospital | Farmington, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Connecticut Health Center | 3678472016 | 523 |
News Archive
Kichitaro Nakajima, a graduate student at the Graduate School of Engineering Science, Hirotsugu Ogi, Associate Professor at the Graduate School of Engineering Science, and Yuji Goto, Professor at Institute for Protein Research, Osaka University succeeded in increasing the velocity constant for a reaction in which proteins causing Alzheimer disease (AD) turn into toxic substances to 1,000 times by using optimum frequency of ultrasonic irradiation.
Scientists at the Roskamp Institute, a not-for-profit biomedical research facility specializing in Alzheimer's disease research, have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder.
Researchers from Boston University School of Medicine (BUSM) and George Washington University (GWU) have developed a method to rapidly identify pathogenic species and strains causing illnesses, such as pneumonia, that could help lead to earlier detection of disease outbreaks and pinpoint effective treatments more quickly.
Healthcare workers who wear gloves while treating patients are much less likely to clean their hands before and after patient contact, according to a study published in the December issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.
› Verified 8 days ago
| Entity Name | Trinity Health Of New England Provider Network Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003882812 PECOS PAC ID: 0941113567 Enrollment ID: O20031110000651 |
News Archive
Kichitaro Nakajima, a graduate student at the Graduate School of Engineering Science, Hirotsugu Ogi, Associate Professor at the Graduate School of Engineering Science, and Yuji Goto, Professor at Institute for Protein Research, Osaka University succeeded in increasing the velocity constant for a reaction in which proteins causing Alzheimer disease (AD) turn into toxic substances to 1,000 times by using optimum frequency of ultrasonic irradiation.
Scientists at the Roskamp Institute, a not-for-profit biomedical research facility specializing in Alzheimer's disease research, have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder.
Researchers from Boston University School of Medicine (BUSM) and George Washington University (GWU) have developed a method to rapidly identify pathogenic species and strains causing illnesses, such as pneumonia, that could help lead to earlier detection of disease outbreaks and pinpoint effective treatments more quickly.
Healthcare workers who wear gloves while treating patients are much less likely to clean their hands before and after patient contact, according to a study published in the December issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.
› Verified 8 days ago
| Entity Name | University Of Connecticut Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720083769 PECOS PAC ID: 3678472016 Enrollment ID: O20040106000105 |
News Archive
Kichitaro Nakajima, a graduate student at the Graduate School of Engineering Science, Hirotsugu Ogi, Associate Professor at the Graduate School of Engineering Science, and Yuji Goto, Professor at Institute for Protein Research, Osaka University succeeded in increasing the velocity constant for a reaction in which proteins causing Alzheimer disease (AD) turn into toxic substances to 1,000 times by using optimum frequency of ultrasonic irradiation.
Scientists at the Roskamp Institute, a not-for-profit biomedical research facility specializing in Alzheimer's disease research, have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder.
Researchers from Boston University School of Medicine (BUSM) and George Washington University (GWU) have developed a method to rapidly identify pathogenic species and strains causing illnesses, such as pneumonia, that could help lead to earlier detection of disease outbreaks and pinpoint effective treatments more quickly.
Healthcare workers who wear gloves while treating patients are much less likely to clean their hands before and after patient contact, according to a study published in the December issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.
› Verified 8 days ago
| Entity Name | Bruce Chozick Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750322251 PECOS PAC ID: 9638163553 Enrollment ID: O20040413001439 |
News Archive
Kichitaro Nakajima, a graduate student at the Graduate School of Engineering Science, Hirotsugu Ogi, Associate Professor at the Graduate School of Engineering Science, and Yuji Goto, Professor at Institute for Protein Research, Osaka University succeeded in increasing the velocity constant for a reaction in which proteins causing Alzheimer disease (AD) turn into toxic substances to 1,000 times by using optimum frequency of ultrasonic irradiation.
Scientists at the Roskamp Institute, a not-for-profit biomedical research facility specializing in Alzheimer's disease research, have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder.
Researchers from Boston University School of Medicine (BUSM) and George Washington University (GWU) have developed a method to rapidly identify pathogenic species and strains causing illnesses, such as pneumonia, that could help lead to earlier detection of disease outbreaks and pinpoint effective treatments more quickly.
Healthcare workers who wear gloves while treating patients are much less likely to clean their hands before and after patient contact, according to a study published in the December issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bruce Steven Chozick, MD 1000 Asylum Ave, Suite 2107a, Hartford, CT 06105-1770 Ph: (860) 714-9840 | Dr Bruce Steven Chozick, MD 1000 Asylum Ave, Suite 2107a, Hartford, CT 06105-1770 Ph: (860) 714-9840 |
News Archive
Kichitaro Nakajima, a graduate student at the Graduate School of Engineering Science, Hirotsugu Ogi, Associate Professor at the Graduate School of Engineering Science, and Yuji Goto, Professor at Institute for Protein Research, Osaka University succeeded in increasing the velocity constant for a reaction in which proteins causing Alzheimer disease (AD) turn into toxic substances to 1,000 times by using optimum frequency of ultrasonic irradiation.
Scientists at the Roskamp Institute, a not-for-profit biomedical research facility specializing in Alzheimer's disease research, have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder.
Researchers from Boston University School of Medicine (BUSM) and George Washington University (GWU) have developed a method to rapidly identify pathogenic species and strains causing illnesses, such as pneumonia, that could help lead to earlier detection of disease outbreaks and pinpoint effective treatments more quickly.
Healthcare workers who wear gloves while treating patients are much less likely to clean their hands before and after patient contact, according to a study published in the December issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.
› Verified 8 days ago
Dr. Brendan Dyer Killory, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 85 Seymour St, Suite 709, Hartford, CT 06106 Phone: 860-696-2290 Fax: 860-696-2280 | |
Kristopher T Kahle, M.D., PH.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 282 Washington St, Hartford, CT 06106 Phone: 860-545-8373 Fax: 860-545-8233 | |
Dr. Paul Joseph Schwartz, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Retreat Ave, Suite 705, Hartford, CT 06106 Phone: 860-278-0070 Fax: 860-522-6081 | |
Dr. Stephan Charles Lange, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 1000 Asylum Ave, Suite 3208, Hartford, CT 06105 Phone: 860-522-7121 Fax: 860-244-3516 | |
Kaveh Barami, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland Street, Hartford, CT 06105 Phone: 904-588-2596 | |
Dr. Jonathan Edward Martin, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 282 Washington St, Suite 1e, Hartford, CT 06106 Phone: 860-545-8373 Fax: 860-545-8233 | |
Joel A. Bauman, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 85 Seymour St, Suite 709, Hartford, CT 06106 Phone: 860-696-2290 Fax: 860-696-2280 |